Royalty Report: Drugs, Disease, Drug Discovery – Collection: 256513

$150.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 11

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 11

Primary Industries

  • Drugs
  • Disease
  • Drug Discovery
  • Therapeutic
  • ribonucleic acid
  • Pharmaceuticals
  • cardiac

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 256305

License Grant
The parties wish to expand their collaboration by engaging in joint activities related to the discovery and development of pharmaceutical products that utilize inventions covered by the Licensor Patents, the Isis Splicing Patents and/or the Licensee Splicing Patents.
License Property
One Party owns or controls certain patents related to morpholino chemistry.

The other Party controls certain patents, the Isis Splicing Patents, related to RNA splicing.

Field of Use
The field of use is to treat Muscular Dystrophy (MD) and Beta Thalassemia (BT).

Muscular dystrophy is a group of diseases that cause progressive weakness and loss of muscle mass.
Beta thalassemia is a blood disorder that reduces the production of hemoglobin. Hemoglobin is the iron-containing protein in red blood cells that carries oxygen to cells throughout the body.

IPSCIO Record ID: 256513

License Grant
The parties wish to expand their collaboration by engaging in joint activities related to the discovery and development of pharmaceutical products that utilize inventions covered by the Licensee Patents, the Isis Splicing Patents and/or the Licensor Splicing Patents.
License Property
One Party owns or controls certain patents related to morpholino chemistry.

The other Party controls certain patents, the Isis Splicing Patents, related to RNA splicing.

Field of Use
The field of use is to treat Muscular Dystrophy (MD) and Beta Thalassemia (BT).

Muscular dystrophy is a group of diseases that cause progressive weakness and loss of muscle mass.
Beta thalassemia is a blood disorder that reduces the production of hemoglobin. Hemoglobin is the iron-containing protein in red blood cells that carries oxygen to cells throughout the body.

IPSCIO Record ID: 27797

License Grant
Licensor hereby grants to Licensee, a Japanese corporation, an exclusive license in the Territory under Patents, Technical Information and the Trademark to develop, have developed, use, have used, make, have made, sell, have sold, distribute and have distributed the Product in the Field, with the right to grant sublicenses.
License Property
Licensee has an interest in the exclusive development of such technologies for the use of Myodur tm brand Product (as hereinafter defined) in the treatment of muscular dystrophy.

Product shall mean the combination of carnitine and leupeptin (and any analogues, conjugates or derivatives thereof) designated by Licensor as the Myodur brand.

Trademark shall mean the Myodur brand as used on and in relation to the Product.

Muscular dystrophy (MD) is a group of muscle diseases that weaken the musculoskeletal system and hamper locomotion.[1][2] Muscular dystrophies are characterized by progressive skeletal muscle weakness, defects in muscle proteins, and the death of muscle cells and tissue.

US Patent 4,742,081 [carnitine]US Patents 4,866,040, 5,008,288 and 5,876,747 [carnitine, aminocarnitine and cysteic acid (taurine)]US and worldwide Patent application for MYODUR specifically in the field of Muscular Dystrophy

Field of Use
Field shall mean Muscular Dystrophy including but not limited to Duchenne's Muscular Dystrophy (DMD) and Becker's Muscular Dystrophy (BMD).

IPSCIO Record ID: 200059

License Grant
The Agreements provide the Licensee with global exclusive rights to the Licensors Duchenne muscular dystrophy (DMD) patent estate for EXONDYS 51 and all future exon-skipping products. The Agreements resolved the ongoing worldwide patent proceedings related to the use of EXONDYS 51 and all future exon-skipping products for the treatment of DMD.
License Property
Duchenne muscular dystrophy (DMD) patent estate for EXONDYS 51.
Muscular dystrophy (MD) is a group of muscle diseases that results in increasing weakening and breakdown of skeletal muscles over time.
Field of Use
Commercialization of pharmaceuticals for the treatment of neuromuscular diseases.

IPSCIO Record ID: 301257

License Grant
Licensor and Licensee will design and identify morpholino and morpholino peptide conjugate splice switching oligomers that modulate the splicing of Licensor-Licensee Exclusive Targets and the Licensee Exclusive Targets. For each Licensor-Licensee Exclusive Target, Licensee will provide Splicing Modulators to be tested for their ability to modulate splicing.

General Overview. Licensor and Licensee will identify and develop Splicing Modulators that modulate the splicing of Licensor-Licensee Exclusive Targets and Licensee Exclusive Targets, as more specifically described in the Research Plan.

Licensor grants to Licensee an exclusive worldwide license to the Splicing Patents solely to research, develop, make and have made, offer for sale, sell, import and export Licensee Exclusive Products.

License Property
Product means an Licensor-Licensee Exclusive Product or an Licensee Exclusive Product, or both.

Licensor-Licensee Exclusive Products are a fixed pool of exclusive Gene Targets for research and development efforts to discover and develop Products that modify such exclusive Gene Targets to develop Splicing Modulators.

Licensee owns or controls certain patents related to morpholino chemistry.

Licensor-Licensee Exclusive Product means a Splicing Modulator that modulates an Licensor-Licensee Exclusive Target and that is Covered by the Licensee Patents and/or an Licensor Invention Patent.

Licensee Exclusive Product means a Splicing Modulator that modulates an Licensee Exclusive Target and is Covered by the Splicing Patents and/or an Licensee Invention Patent.

Splicing Modulator means an oligonucleotide or analog thereof that selectively modulates RNA Splicing or polyadenylation by a non-Rnase dependent mechanism at the nucleic acid level by specifically binding to the sequence of a selected messenger or viral ribonucleic acid (RNA) by base-pairing, thus causing a selective pattern of gene expression.

Licensee Patents means the patent(s) listed.
5,142,047 – Uncharged polynucleotide-binding polymers

Splicing Patents means the Isis Splicing Patents and the Licensor Splicing Patents.

Licensor Splicing Patents means the patent(s) listed.
5,976,879 – Antisense oligonucleotides which combat aberrant splicing and methods of using the same

Isis Splicing Patents means the patent(s) listed.
6,210,892 – Alteration of cellular behavior by antisense modulation of mRNA processing

Licensee Invention Patent and/or Licensor Invention Patent has the meaning depending how any Inventions are made under the Research Plan will define if it is an Licensor Invention or an Licensee Invention, as the case may be, and Patents claiming such Inventions will be Licensor Invention Patents or Licensee Invention Patents, respectively.

Licensor-Licensee Exclusive Target also known as Gene Targets that are selected for their research and development efforts.
List of the five selected Targets
TNFRl
TNFR2
He.r2
BCL-X
CD28

Licensee Exclusive Target also known as Gene Targets that are selected for their research and development efforts.
List of the five selected Targets
PDl
CTLA4
TGF beta
P53
IL23

Field of Use
This agreement pertains to the drug industry related to RNA splicing in the areas of drug discovery and medicinal chemistry,

IPSCIO Record ID: 291167

License Grant
Licensee and Licensor will design and identify morpholino and morpholino peptide conjugate splice switching oligomers that modulate the splicing of Licensee-Licensor Exclusive Targets and the Licensor Exclusive Targets. For each Licensee-Licensor Exclusive Target, Licensor will provide Splicing Modulators to be tested for their ability to modulate splicing.

Licensee and Licensor will design and identify morpholino and morpholino peptide conjugate splice switching oligomers that modulate the splicing of Licensee-Licensor Exclusive Targets and the Licensor Exclusive Targets. For each Licensee-Licensor Exclusive Target, Licensor will provide Splicing Modulators to be tested for their ability to modulate splicing.

General Overview. Licensee and Licensor will identify and develop Splicing Modulators that modulate the splicing of Licensee-Licensor Exclusive Targets and Licensor Exclusive Targets, as more specifically described in the Research Plan.

Licensor grants Licensee the following licenses
Licensor grants Licensee an exclusive worldwide license to the Licensor Patents solely to research, develop, offer for sale, sell, import and export Licensee-Licensor Exclusive Products.

License Property
Product means an Licensee-Licensor Exclusive Product or an Licensor Exclusive Product, or both.

Licensor-Licensee Exclusive Products are a fixed pool of exclusive Gene Targets for research and development efforts to discover and develop Products that modify such exclusive Gene Targets to develop Splicing Modulators.

Licensor owns or controls certain patents related to morpholino chemistry.

Licensee-Licensor Exclusive Product means a Splicing Modulator that modulates an Licensee-Licensor Exclusive Target and that is Covered by the Licensor Patents and/or an Licensee Invention Patent.

Licensor Exclusive Product means a Splicing Modulator that modulates an Licensor Exclusive Target and is Covered by the Splicing Patents and/or an Licensor Invention Patent.

Splicing Modulator means an oligonucleotide or analog thereof that selectively modulates RNA Splicing or polyadenylation by a non-Rnase dependent mechanism at the nucleic acid level by specifically binding to the sequence of a selected messenger or viral ribonucleic acid (RNA) by base-pairing, thus causing a selective pattern of gene expression.

Licensor Patents means the patent(s) listed.
5,142,047 – Uncharged polynucleotide-binding polymers

Splicing Patents means the Isis Splicing Patents and the Licensee Splicing Patents.

Licensee Splicing Patents means the patent(s) listed.
5,976,879 – Antisense oligonucleotides which combat aberrant splicing and methods of using the same

Isis Splicing Patents means the patent(s) listed.
6,210,892 – Alteration of cellular behavior by antisense modulation of mRNA processing

Licensor Invention Patent and/or Licensee Invention Patent has the meaning depending how any Inventions are made under the Research Plan will define if it is an Licensee Invention or an Licensor Invention, as the case may be, and Patents claiming such Inventions will be Licensee Invention Patents or Licensor Invention Patents, respectively.

Licensee-Licensor Exclusive Target also known as Gene Targets that are selected for their research and development efforts.
List of the five selected Targets
TNFRl
TNFR2
He.r2
BCL-X
CD28

Licensor Exclusive Target also known as Gene Targets that are selected for their research and development efforts.
List of the five selected Targets
PDl
CTLA4
TGF beta
P53
IL23

Field of Use
This agreement pertains to the drug industry related to RNA splicing in the areas of drug discovery and medicinal chemistry,

IPSCIO Record ID: 239657

License Grant
License grants the Licensee  exclusive, worldwide rights to AXO-AAV-OPMD utilizing proprietary Silence-and-Replace technology, which suppresses mutant protein production while restoring expression of functional protein.   License also grants rights to five additional investigational gene therapy products for neurological conditions.
License Property
An investigational Silence-and-Replace gene therapy program for the treatment of oculopharyngeal muscular dystrophy.  The Silence-and-Replace gene therapy technology is designed to deliver a combination of DNA-directed RNA interference (silence) along with a functional copy of the gene (replace) in a single vector construct.
Field of Use
The AXO-AAV-OPMD Program is an investigational gene therapy being developed as a one-time treatment for oculopharyngeal muscular dystrophy.

Oculopharyngeal muscular dystrophy (OPMD) is a rare genetic muscle disorder with onset during adulthood most often between 40 and 60 years of age. OPMD is characterized by slowly progressive muscle disease (myopathy) affecting the muscles of the upper eyelids and the throat.

IPSCIO Record ID: 295927

License Grant
Licensor granted Licensee worldwide exclusive licenses, with the right to grant sublicenses, to our patent rights and know-how with respect to such compounds and products. Licensee is responsible for pursuing worldwide clinical development of compounds from the research program and has the exclusive right to develop and commercialize compounds from the collaboration  to further develop and commercialize compounds identified under our Foundation sponsored research program with the Foundation and to research other small molecule compounds with potential for therapeutic use in patients with Foundation.
License Property
Licensor developed several high-throughput drug discovery technology platforms that enable us to identify small molecule modifiers of pre-mRNA splicing. These technologies rely on sensitive quantification of pre-mRNA isoforms directly in human cells or tissue samples. Using this technology, we have successfully identified orally bioavailable small molecules that correct splicing of SMN2 mRNA. One of these molecules, risdiplam, is a potential treatment for the genetic disorder SMA.
Field of Use
The small molecule compounds with the potential for therapeutic use in patients with Spinal Muscular Atrophy (SMA).

Spinal muscular atrophy is a genetic disorder characterized by weakness and wasting (atrophy?) in muscles used for movement (skeletal muscles). It is caused by a loss of specialized nerve cells, called motor neurons that control muscle movement. The weakness tends to be more severe in the muscles that are close to the center of the body (proximal) compared to muscles away from the body's center (distal). The muscle weakness usually worsens with age.

IPSCIO Record ID: 286043

License Grant
Licensor hereby grants to Licensee an exclusive sublicense under the Licensed Patents in the Field of Use to make and have made, manufacture and have manufactured Agreement Compounds and Licensed Products from Agreement Compounds for sale in the Territory and to use and have used and lease, sell and have sold Licensed  Products, and to practice the Licensed Processes, and Improvements, with the right to grant sublicenses (with the prior written consent of Licensor, which consent shall not be unreasonably withheld), in the Territory and Licensor further grants to Licensee an exclusive sublicense  to use the Know-How to make and have made, manufacture  and have manufactured Agreement Compounds and Licensed Products from Agreement Compounds for sale in the Territory and to use the Know-How to use and hav  used and lease, sell and have sold Licensed Products, and to practice the Licensed Processes, and Improvements, with the right to grant sublicenses (with the prior written consent of Licensor, which consent shall not be unreasonably withheld), in the Territory.
License Property
Licensed Patents means all of the intellectual property, granted to Licensor identified herein as Agreement  Compounds for the described Field of Use.

Patent Application # U.S.S.N. 60/073,603 entitled 'N,N-Bis(2-Hydroxybenzyl) Ethylenediamine-N,N-Diacetic Acid in Iron Chelating Theraphy'.

Agreement  Compounds means the monosodium salt of N,N-bis (2-hydroxybenzyl) ethylenediamine-N,N diacetic acid (hereinafter 'NaHBED' or 'HBED'), or any other mono-cation salt of HBED.

Intellectual property relates to develop and market a proprietary iron chelator.  Iron chelation therapy is the removal of excess iron from the body with special drugs.

Field of Use
Field of Use means iron overload conditions, including, but not limited to, Thalassemia, sickle-cell anemia, and myelodysplasia (but excluding neuro- degenerative disorders), but shall exclude uses of Agreement Compounds by a route of delivery other than subcutaneous or IM injection or IV infusion or transdermal.

Thalassemia is a blood disorder passed down through families (inherited) in which the body makes an abnormal form or inadequate amount of hemoglobin. Hemoglobin is the protein in red blood cells that carries oxygen. The disorder results in large numbers of red blood cells being destroyed, which leads to anemia.

Sickle cell anemia is an inherited form of anemia — a condition in which there aren't enough healthy red blood cells to carry adequate oxygen throughout your body.

Myelodysplastic syndromes (MDS) are a group of cancers in which immature blood cells in the bone marrow do not mature and therefore do not become healthy blood cells.

IPSCIO Record ID: 198450

License Grant
The Netherland Licensor parties granted the Licensee a royalty-bearing, worldwide license under patent rights and know-how with respect to the  Duchenne muscular dystrophy program, which are potentially necessary or useful for the treatment of DMD,  in all fields of use and for all purposes, including to develop and commercialize antisense oligonucleotide products that target one or more exons of the dystrophin gene to induce exon skipping, including eteplirsen.
License Property
IP includes the disease-modifying pipeline of exon-skipping drug candidates targeting Duchenne muscular dystrophy.
Duchenne muscular dystrophy (DMD) is a genetic disorder characterized by progressive muscle degeneration and weakness.
Field of Use
The Licensee is a biopharmaceutical company focused on the discovery and development of unique RNA-targeted therapeutics for the treatment of rare neuromuscular diseases.

IPSCIO Record ID: 372543

License Grant
The Contribution Agreement is relating to the development of License Product.

This Amendment is for changes with respect to the development of Licensed Product, as well as, changes to allow the Licensee, in certain circumstances, to return either Licensors 101 or 102, as applicable, to Licensor without terminating the Agreement.

If the Licensee determines, in its sole and reasonable discretion, that it is commercially reasonable for the Licensee to discontinue development of a Licensed Product incorporating either Licensors 101 or 102, then, upon prior written notice by the Licensee to Licensor of such facts, the parties agree that the Licensee shall be free to cease and shall cease all development activities relating to such Licensed Product incorporating either Licensors 101 or 102.

License Property
The licensed property relates to Deferiprone, a bidentate oral iron chelator.

Deferiprone is an oral iron chelator used to treat patients with iron overload due to the frequent blood transfusions required in certain disorders such as thalassemia.

Field of Use
The field of use is for the treatment of iron overload in patients with thalassemia major for whom deferoxamine therapy is contraindicated or inadequate.

Thalassemia is an inherited blood disorder that causes your body to have less hemoglobin than normal. Hemoglobin enables red blood cells to carry oxygen. Thalassemia can cause anemia, leaving you fatigued. If you have mild thalassemia, you might not need treatment.
Deferoxamine is an iron-chelating agent that binds free iron in a stable complex, preventing it from engaging in chemical reactions. Deferoxamine chelates iron from intra-lysosomal ferritin and siderin forming ferrioxamine, a water-soluble chelate excreted by the kidneys and in the feces via the bile.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.